- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Presentation 1: Oncology Practice in the Era of PCMHs and ACOs: Square Pegs or Round Holes?
Dr Peter Bach says professionals are looking at opportunities for new payment models and care redesign, but there are also threats that might surface. Each type of insurance payment model has different levels of risk factors. New payment models, such as the UHC pathways program and CMMI demo, have limited risk.
Dr Peter Bach says professionals are looking at opportunities for new payment models and care redesign, but there are also threats that might surface. Each type of insurance payment model has different levels of risk factors. New payment models, such as the UHC pathways program and CMMI demo, have limited risk.
In regard to the future of payment, Dr Bach suggests that models such as the patient-centered medical home and accountable care organization, which boast shared savings, are likely to be useful. For oncology, the general “thrust” is to find savings outside drug expenditures, including reduced use of testing and avoiding hospitalization costs. “The general trend is to move risk, and it’s to move it where the discretionary decisions are made,” says Dr Bach. “It’s not a question of if, but when.”
Dr Bach also elaborates on why the site of care matters. Programs such as 340B, which offers discount drugs to hospitals that treat large populations of poor patients, impact costs. Finally, Bach suggests how this shift in site of care could benefit oncology patients.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Powles Highlights “Transformative” Benefit of EV Plus Pembro While Sharing Long-Term Data for EV-302
February 15th 2025The lead investigator for EV-302 said not long ago, survival of 12 to 14 months in this type of bladder cancer was considered an achievement; in this study, median overall survival was 34 months after treatment with enfortumab vedotin (EV) and pembrolizumab (pembro).
Read More
Analysis Looks at Benefits, Toxicity of ADC Combinations in Advanced Bladder Cancer
February 15th 2025City of Hope's Salvador Jaime-Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody-drug conjugate (ADC) combinations in advanced urothelial cancer.
Read More
